Heart watch: simple blood test may shield cancer patients from therapy damage
NCT ID NCT06337097
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This study is testing whether checking troponin levels in the blood before each dose of immune checkpoint therapy can help catch heart problems early. 980 cancer patients will either get regular troponin monitoring or standard care. The goal is to see if this approach lowers heart-related side effects from treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT THERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Troponin surveillance (blood test)
What this could lead to
If successful, this could show that routine heart monitoring during immunotherapy helps catch and prevent heart problems early.
What could go wrong
This is an observational study, not a treatment trial. It may not prove that monitoring actually reduces heart issues, and results may not apply to all patients.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.